logo
logo

Chroma Medicine Secures $135M In Series B Financing To Advance Breakthrough Epigenetic Editing Technology And Expand Pipeline Of Durable Precision Genomic Medicines

Mar 01, 2023•over 2 years ago

Amount Raised

$135 Million

Round Type

series b

BostonGeneticsTherapeuticsBiotechnologyHealth Care

Investors

Wellington ManagementT Rowe PriceSofinnova PartnersOsage University PartnersOmega FundsNewpath PartnersJanus Henderson InvestorsCormorant Asset ManagementCasdin CapitalAtlas VentureAlexandria Venture InvestmentsArch Venture PartnersGv ,Sixth StreetMubadala CapitalDcvc BioArch Venture PartnersGv

Description

Chroma Medicine, Inc., (Chroma) a genomic medicine company pioneering single-dose epigenetic editing therapeutics, today announced the completion of a $135 million Series B financing led by GV (Google Ventures), with participation from additional new investors ARCH Venture Partners, DCVC Bio, Mubadala Capital, Sixth Street, and all existing investors, including Alexandria Venture Investments, Atlas Venture, Casdin Capital, Cormorant Asset Management, Janus Henderson Investors, Newpath Partners, Omega Funds, Osage University Partners, Sofinnova Partners, T Rowe Price, and Wellington Management. The financing will support advancement of Chroma's therapeutic programs toward the clinic, and continued investment in the company's core epigenetic editing platform.

Company Information

Company

Chroma Medicine

Location

Boston, Massachusetts, United States

About

Chroma Medicine is pioneering a new class of single-dose genomic medicines that harness epigenetics, nature’s innate mechanism for gene regulation, revolutionizing the treatment of disease. Epigenetics is nature’s central mechanism for gene regulation, governing cell phenotype and function by precisely controlling gene activity without changing the underlying DNA sequence. Building on groundbreaking research from the world’s foremost genomic medicine experts, Chroma Medicine is working at the cutting edge of precision genomics, building an entirely new class of therapeutics to achieve unparalleled control of gene expression. *Note: Be aware of fraudulent recruiting advertisements and scams: Potential candidates for employment at Chroma Medicine should be aware of job offer fraud scams perpetrated through the use of the internet and social media platforms. To learn more, please visit the Join Us page on our website.

Funding Insights

Based on industry data
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Related People